RELMADA THERAPEUTICS, INC. Capital Expenditures
RELMADA THERAPEUTICS, INC. (RLMD) reported Capital Expenditures of -$1.80 thousand for the 33-month period ending 2014-02-28, per its 10-Q filed 2014-04-15.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2014-04-15
- RELMADA THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2014-02-28 was $0.00.
- RELMADA THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2013-11-30 was $0.00.
- RELMADA THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2013-08-31 was $0.00.
- RELMADA THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2013 was -$1.80K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month | Payments to Acquire Property, Plant, and Equipment 24 month | Payments to Acquire Property, Plant, and Equipment 27 month | Payments to Acquire Property, Plant, and Equipment 30 month | Payments to Acquire Property, Plant, and Equipment 33 month |
|---|---|---|---|---|---|---|---|---|
| 2014-02-28 | $0.00 derived: 10-Q 33 month − 10-Q 30 month · filed 2014-04-15 | $0.00 derived: sum of 2 quarters · filed 2014-04-15 | $0.00 derived: sum of 3 quarters · filed 2014-04-15 | -$1.80K 10-Q · filed 2014-04-15 | ||||
| 2013-11-30 | $0.00 derived: 10-Q 30 month − 10-K 27 month · filed 2014-01-13 | $0.00 derived: sum of 2 quarters · filed 2014-01-13 | -$1.80K 10-Q · filed 2014-01-13 | |||||
| 2013-08-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-12-16 | -$1.80K 10-K · filed 2013-12-16 | -$1.80K 10-K · filed 2013-12-16 | |||||
| 2013-05-31 | -$1.80K 10-Q · filed 2013-07-12 | -$1.80K 10-Q · filed 2013-07-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |